Lovastatin

Product Description

Lovastatin is a potent, competitive inhibitor of HMG-CoA reductase (K_i = 0.6 nM) therefore decreases cholesterol biosynthesis, in vitro and in vivo. Indirectly inhibits Rho-GTPase activity by depleting intracellular pool of isoprene residues. Decreases CDK2, 4, 6 and cyclin E levels and induces G1 arrest and apoptosis in tumor cell lines in vitro. Inactive lactam prodrug of lovastatin hydroxy acid, naturally bioactivated in vivo following oral administration.

Solubility

Preparing Stock Solutions for Lovastatin

The following data is based on the product molecular weight 404.54

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.47 mL	12.36 mL	24.72 mL
5 mM	0.49 mL	2.47 mL	4.94 mL
10 mM	0.25 mL	1.24 mL	2.47 mL
50 mM	0.05 mL	0.25 mL	0.49 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Ziegler Rho inhibition by lovas. affects apoptosis and DSB repair of primary human lung cells in vitro and lung tissue in vivo following fractionated irradiation. Cell Death Dis. 2017 PMID: 28796249
• Alberts Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc.Natl.Acad.Sci.U.S.A. 1980 PMID: 6933445
• Park Lovastatin-induced inhibition of HL-60 cell proliferation via cell cycle arrest and apoptosis. Anticancer Res. 1999 PMID: 10652602
• Alberts Discovery, biochemistry and biology of lovas. Am.J.Cardiol. 1988 PMID: 3055919